SHH and breast cancer: Although improper SHH signaling can arise from a variety of mechanisms (see Section 5 above), aberrant SHH signaling in breast cancer tends to occur through Type II ligand-dependent signaling in which tumors cells profusely secrete active SHH ligand into the immediate surrounding area, leading to self-activation or activation of juxtaposed tumor cells [193,252].